Home > Pulmonology > ATS 2022 > SPRINTER still in the running?

SPRINTER still in the running?

Presented By
Dr Phillip Monk, Synairgen Research LtD, UK
ATS 2022
A post hoc analysis of the SPRINTER trial suggests that the inhaled, interferon-β investigational agent for COVID-19, known as SNG001, may provide a beneficial effect with respect to prevention of severe disease or death, despite not meeting its primary endpoint. These results provide a potential clinical rationale to continue the investigation of SNG001 in progression and/or mortality in hospitalised patients with COVID-19. Dr Phillip Monk (Synairgen Research LtD, UK) presented the post hoc analyses of the phase 3, randomised, placebo-controlled, double-blind, SPRINTER study (NCT04732949) [1]. The rationale behind this trial was based on recent promising phase 2 results [2]. SPRINTER assessed the efficacy and safety of SNG001 for the treatment of adults hospitalised due to COVID-19 who required treatment with supplemental oxygen by mask or nasal prongs. Pat...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on